Global Hormonal Replacement Therapy Drugs Market Report 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Drugs For Hormonal Replacement Therapy Global Market Report 2020” report has been added to ResearchAndMarkets.com’s offering.

The global drugs for hormonal replacement therapy market was valued at about $5.02 billion in 2018 and is expected to grow to $7.09 billion at a CAGR of 9.0% through 2022.

Drugs for Hormonal Replacement Therapy market consists of sales of drugs for hormonal replacement therapy and related services. The drugs for hormonal replacement therapy are used to treat patients with growth hormone deficiency caused due to conditions such as dwarfism or menopause (a condition which describes changes a women goes through when her menstruating cycle stops). The drugs for hormonal replacement therapy help to replace low level hormones from the body, maintain growth hormone deficiency and prevent women from vaginal dryness, mood swings, weakening of bones and others.

North America was the largest region in the drugs for hormonal replacement therapy market in 2016. This region is expected to remain the largest during the next five years. The drugs for hormonal replacement therapy market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

Increasing population of aging and postmenopausal women is driving the drugs for hormonal replacement therapy market growth. Hormonal replacement therapy drugs such as Estrogen, Progestin and others are used to treat medical conditions caused due to menopausal conditions. In 2018, according to a report by The Indian Menopause Society, New Delhi, in India there are 65 million women over the menopausal age affected with menopausal symptoms. According to European Menopause and Andropause Society (EMAS) report, women aged over 60 are expected to reach over 1 billion by 2050.

Furthermore, out of the global women population in 2015, 54% of them were aged over 60 and 62% of them were aged over 80. In 2015, in South Korea, the female population is expected to exceed male population by 2060, out of which 59.6% of female population is expected to suffer from postmenopausal symptoms. Thus, growing women population suffering from menopausal symptoms and aging population drives the market for hormonal replacement therapy drugs market.

Increasing occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder growth of drugs for hormonal replacement therapy market. The side effects include vagina dryness, irregular heartbeat, breast swelling, osteoporosis (weakening of bones) and other effects when women undergo hormonal replacement therapy. High dosage of drugs for hormonal replacement therapy may cause rapid heartbeat, bloating (a buildup of gas in the stomach and intestines), nausea, indigestion, vaginal bleeding, blood clots, heart attack, breast cancer and others.

Companies in the industry are increasingly developing of drugs for hormonal replacement therapy with better safety profiles and novel drug delivery mechanisms. The drug delivery mechanisms include transdermal estrogen, varginal estrogen and others. Transdermal estrogen drug delivery is in the form of estradiol transdermal gel, patch, and spray that are used to treat symptoms of menopause, vaginal dryness, itching, burning and others occur due to low estrogen levels. Varginal estrogen in the form of cream, vaginal ring, vaginal tablets are used to get the hormone estrogen into the system.

For instance, Novo Nordisk, a multinational pharmaceutical company provides novel drug delivery mechanisms and low dose drugs for hormonal replacement therapy (HRT) to cater to the rising demand of patient needs. Some of the brands offering of novel drugs include Climara, Divigel, Elestrin, Esclim, Estraderm, Estrasorb, EstroGel, Evamist, Oesclim, Rhoxal-Estradiol Derm 50, Vivelle 100 Mcg, Estradot Transdermal Therapeutic System and others.

Department Of Health And Human Services of Food And Drug Administration (FDA), a federal agency, is a regulatory body monitoring, controlling and regulating the drugs for hormonal replacement therapy market. In April 2018, FDA’s Department Of Health And Human Services has revised the requirements of specific hormone-containing drug products for human use. These hormones include estrogens, progestin’s, androgens, anabolic steroids, adrenal corticosteroids, and synthetic analogs. The purpose of the revisal of existing regulations by FDA is to establish effectiveness and ensure safety for any over-the-counter drug use of these ingredients.

Major players in the market are Novartis AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company

Companies Mentioned

• Abbott
• Mylan Laboratories
• Merck & Co
• Hisamitsu Pharmaceutical Co Inc
• Teva Pharmaceutical Industries Ltd.,
• F. Hoffmann-La Roche
• Noven Pharmaceuticals,Inc.
• Orion Pharma AB
• Allergan Plc
• QuatRx Pharmaceuticals
• Wyeth
• Amgen Inc.
• Roche
• Genentech
• TherapeuticsMD

For more information about this report visit https://www.researchandmarkets.com/r/306vnw

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900